Literature DB >> 9609751

Clinical course of colorectal Crohn's disease: a 35-year follow-up study of 507 patients.

A Lapidus1, O Bernell, G Hellers, R Löfberg.   

Abstract

BACKGROUND & AIMS: Crohn's disease (CD) confined to the colon and rectum is an increasing clinical entity. The aim of this study was to assess the features and clinical course of colorectal CD.
METHODS: This was a retrospective cohort study of 507 patients in whom colonic or rectal CD had been diagnosed between 1955 and 1989.
RESULTS: Colonic distribution was segmental in 40%, total in 31%, and left-sided in 26%. Perianal/rectal fistulas occurred in 37%. In patients who attained clinical remission, the 5-year cumulative relapse rate after diagnosis was 67% (95% confidence interval [CI], 62-72). At the initial presentation of CD, the frequency of major surgery decreased from 24% to 14% (P < 0.005) over time. Still, the overall long-term probability of major surgery after 10 years was unaltered (49% vs. 47%). The presence of fistulas increased the probability of surgical resection (relative risk [RR], 1.7 [95% CI, 1.3-2.2]), whereas left-sided disease was associated with a decrease (RR, 0.6 [95% CI, 0.4-0.8]). Twenty-four percent of the patients developed inflammation in the small bowel. The cumulative risk for a permanent ileostomy was 25% (95% CI, 21-29) 10 years after diagnosis.
CONCLUSIONS: Colorectal CD is an increasing entity carrying substantial morbidity. Half of the patients will undergo surgical resection within the first 10 years, and half of those will ultimately undergo ileostomy. Changed management at diagnosis has not affected the long-term probability of resection.

Entities:  

Mesh:

Year:  1998        PMID: 9609751     DOI: 10.1016/s0016-5085(98)70420-2

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  34 in total

Review 1.  Anti-TNF antibody treatment of Crohn's disease.

Authors:  S J van Deventer
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

2.  Changes in surgical therapy for Crohn's disease over 33 years: a prospective longitudinal study.

Authors:  Michael Siassi; Alexander Weiger; Werner Hohenberger; Hermann Kessler
Journal:  Int J Colorectal Dis       Date:  2006-05-30       Impact factor: 2.571

3.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

Review 4.  Perianal Crohn's disease: is there something new?

Authors:  Cesare Ruffolo; Marilisa Citton; Marco Scarpa; Imerio Angriman; Marco Massani; Ezio Caratozzolo; Nicolò Bassi
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

Review 5.  Imaging techniques and combined medical and surgical treatment of perianal Crohn's disease.

Authors:  F Botti; A Losco; C Viganò; B Oreggia; M Prati; E Contessini Avesani
Journal:  J Ultrasound       Date:  2013-10-24

6.  Long-term success rate after surgical treatment of anorectal and rectovaginal fistulas in Crohn's disease.

Authors:  Thorsten Löffler; Thilo Welsch; Stefanie Mühl; Ulf Hinz; Jan Schmidt; Peter Kienle
Journal:  Int J Colorectal Dis       Date:  2009-01-27       Impact factor: 2.571

Review 7.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 8.  Restorative procedures in colonic crohn disease.

Authors:  Sean T Martin; Jon D Vogel
Journal:  Clin Colon Rectal Surg       Date:  2013-06

9.  Long-Term Outcomes of Infliximab Treatment in 582 Korean Patients with Crohn's Disease: A Hospital-Based Cohort Study.

Authors:  Sang Hyoung Park; Sung Wook Hwang; Min Seob Kwak; Wan Soo Kim; Jeong-Mi Lee; Ho-Su Lee; Dong-Hoon Yang; Kyung-Jo Kim; Byong Duk Ye; Jeong-Sik Byeon; Seung-Jae Myung; Yong Sik Yoon; Chang Sik Yu; Jin-Ho Kim; Suk-Kyun Yang
Journal:  Dig Dis Sci       Date:  2016-03-12       Impact factor: 3.199

10.  Adalimumab for the treatment of fistulas in patients with Crohn's disease.

Authors:  J-F Colombel; D A Schwartz; W J Sandborn; M A Kamm; G D'Haens; P Rutgeerts; R Enns; R Panaccione; S Schreiber; J Li; J D Kent; K G Lomax; P F Pollack
Journal:  Gut       Date:  2009-02-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.